Poland· PL-100423594
Trecondi
A treosulfan product containing treosulfanum, registered in Poland by medac Gesellschaft fuer klinische Spezialpraeparate mbH. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Treosulfan is registered in 16 of 19 countries.
Countries holding a registration under ATC L01AB02 (treosulfan), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Treosulfan · ATC L01AB02
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Treosulfanum
- Manufacturer
- medac Gesellschaft fuer klinische Spezialpraeparate mbH
- Country
- Poland (PL)
- ATC code
- L01AB02
- ATC class
- Treosulfan
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991411343
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Treosulfan in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTRECONDIMedac Gesellschaft für klinische Spezialpräparate m.b.H., Wedel
- SpainTRECONDI 5 G POLVO PARA SOLUCION PARA PERFUSIONMedac Gesellschaft Für Klinische Spezialpräparate Gmbh
- FinlandTrecondiMedac Gesellschaft Für Klinische Spezialpräparate mbH
- BelgiumTrecondi 5 gMedac
- SwedenTrecondi 5 g Pulver till infusionsvätska, lösningmedac Gesellschaft für klinische Spezialpräparate mbH
- IcelandTrecondimedac Gesellschaft für klinische Spezialpräparate GmbH
- NorwayTrecondiMedac - Gesellschaft für klinische Spezialpräparate Gmbh - Wedel
- IrelandTreosulfan Tillomed 5 g powder for solution for infusionLaboratorios Tillomed Spain, S.L.U.
Authorised across Europe · EMA
The same active substance is authorised in 18 EEA countries. Names it is sold under:
- Austria · Treosulfan Tillomed
- Belgium · Treosulfan Tillomed
- Czechia · Treosulfan Tillomed
- Germany · Ovastat, Treosulfan Tillomed
- Denmark · Treosulfan Tillomed
- Spain · Treosulfano Zentiva
- Finland · Treosulfan Tillomed
- France · Treosulfan Tillomed
- United Kingdom (Northern Ireland) · Treosulfan Tillomed Laboratories
- Greece · Treosulfan Tillomed
- Ireland · Treosulfan Tillomed
- Iceland · Trecondi
- Liechtenstein · Trecondi
- Netherlands · Treosulfan Tillomed
- Norway · Trecondi, Treosulfan Tillomed
- Portugal · Treossulfano Tillomed
- Romania · Treosulfan Tillomed
- Sweden · Treosulfan Tillomed
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/692603ad-32d9-4259-b0e6-77c68063a2e9 GET /v1/drugs/692603ad-32d9-4259-b0e6-77c68063a2e9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "5 g",
"packaging": "Rpz ¦ EU/1/18/1351/003 ¦ 133637\n1 fiol. proszku\n05909991411343 ¦ Rpz ¦ EU/1/18/1351/004 ¦ 133638\n5 fiol. proszku",
"substance": "Treosulfan 5 g",
"common_name": "Treosulfanum",
"pl_product_id": "100423594",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about treosulfan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.